Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: medac, Gesellschaft für klinische Spezialpräparate mbH, Theaterstr. 6, 22880 Wedel, Germany, Tel.: +49 4103 8006-0, Fax: +49 4103 8006-100
Metoject PEN is indicated for the treatment of:
Metoject PEN should only be prescribed by physicians who are familiar with the various characteristics of the medicinal product and its mode of action. Patients must be educated to use the proper injection technique. The first injection of Metoject PEN should be performed under direct medical supervision. Metoject PEN is injected once weekly.
The patient must be explicitly informed about the fact that Metoject PEN is administered once a week only. It is advisable to determine an appropriate fixed day of the week for the injection.
Methotrexate elimination is reduced in patients with a third distribution space (ascites, pleural effusions). Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration (see section 5.2 and 4.4).
The recommended initial dose is 7.5 mg of methotrexate once weekly, administered subcutaneously. Depending on the individual activity of the disease and tolerability by the patient, the initial dose may be increased gradually by 2.5 mg per week. A weekly dose of 25 mg should in general not be exceeded. Doses exceeding 20 mg/week are associated with significant increase in toxicity, especially bone marrow suppression. Response to treatment can be expected after approximately 4-8 weeks. Upon achieving the therapeutically desired result, the dose should be reduced gradually to the lowest possible effective maintenance dose.
The recommended dose is 10-15 mg/m² body surface area (BSA)/once weekly. In therapy-refractory cases the weekly dosage may be increased up to 20 mg/m² body surface area/once weekly. However, an increased monitoring frequency is indicated if the dose is increased.
Due to limited data availability about intravenous use in children and adolescents, parenteral administration is limited to subcutaneous injection.
Patients with JIA should always be referred to a rheumatology specialist in the treatment of children/adolescents.
Use in children <3 years of age is not recommended as insufficient data on efficacy and safety is available for this population (see section 4.4).
It is recommended that a test dose of 5-10 mg should be administered parenterally, one week prior to therapy to detect idiosyncratic adverse reactions. The recommended initial dose is 7.5 mg of methotrexate once weekly, administered subcutaneously. The dose is to be increased gradually but should not, in general, exceed a weekly dose of 25 mg of methotrexate. Doses exceeding 20 mg per week can be associated with significant increase in toxicity, especially bone marrow suppression. Response to treatment can generally be expected after approximately 2-6 weeks. Upon achieving the therapeutically desired result, the dose should be reduced gradually to the lowest possible effective maintenance dose.
The dose should be increased as necessary but should in general not exceed the maximum recommended weekly dose of 25 mg. In a few exceptional cases a higher dose might be clinically justified, but should not exceed a maximum weekly dose of 30 mg of methotrexate as toxicity will markedly increase.
Induction treatment: 25 mg/week administered subcutaneously.
Response to treatment can be expected after approximately 8 to 12 weeks.
Maintenance treatment: 15 mg/week administered subcutaneously.
There is not sufficient experience in the paediatric population to recommend Metoject PEN for the treatment of Crohn’s disease in this population.
Metoject PEN should be used with caution in patients with impaired renal function. The dose should be adjusted as follows:
Creatinine clearance (ml/min) | Dose |
---|---|
≥60 | 100% |
30-59 | 50% |
<30 | Metoject PEN must not be used |
See section 4.3.
Methotrexate should be administered with great caution, if at all, to patients with significant current or previous liver disease, especially if due to alcohol. If bilirubin is >5 mg/dl (85.5 µmol/l), methotrexate is contraindicated.
For the full list of contraindications, see section 4.3.
Dose reduction should be considered in elderly patients due to reduced liver and kidney function as well as lower folate reserves which occur with increased age.
As the half-life of methotrexate can be prolonged to 4 times the normal length in patients who possess a third distribution space dose reduction or, in some cases, discontinuation of methotrexate administration may be required (see section 5.2 and 4.4).
The medicinal product is for single use only.
Metoject PEN solution for injection in pre-filled pen can only be given by subcutaneous route.
The overall duration of the treatment is decided by the physician.
Guidance on how to use Metoject PEN solution for injection in pre-filled pen can be found in section 6.6.
Please note that all of the contents have to be used.
Note:
If changing the oral application to parenteral administration a reduction of the dose may be required due to the variable bioavailability of methotrexate after oral administration.
Folic acid supplementation may be considered according to current treatment guidelines.
Toxicity of methotrexate mainly affects the haematopoietic system.
Calcium folinate is the specific antidote for neutralising the toxic undesirable effects of methotrexate.
In cases of accidental overdose, a dose of calcium folinate equal to or higher than the offending dose of methotrexate should be administered intravenously or intramuscularly within one hour and dosing continued until the serum levels of methotrexate are below 10-7 mol/l.
In cases of massive overdose, hydration and urinary alkalisation may be necessary to prevent precipitation of methotrexate and/or its metabolites in the renal tubules. Neither haemodialysis nor peritoneal dialysis has been shown to improve methotrexate elimination. Effective clearance of methotrexate has been reported with acute, intermittent haemodialysis using a high flux dialyser.
Shelf life: 2 years.
Store below 25°C. Keep the pre-filled pens in the outer carton in order to protect from light.
Pre-filled pens containing a colourless pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and embedded injection needle. The syringe is externally equipped with the device for self-administration (pen).
Pack sizes:
Pre-filled pens containing 0.15 ml (7.5 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.2 ml (10 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.25 ml (12.5 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.3 ml (15 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.35 ml (17.5 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.4 ml (20 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.45 ml (22.5 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.5 ml (25 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.55 ml (27.5 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Pre-filled pens containing 0.6 ml (30 mg) solution are available in packs of 1, 2, 4, 5, 6, 10, 11, 12, 14, 15, and 24 pre-filled pens.
Alcohol pads are included in the package.
Not all pack sizes may be marketed.
The manner of handling and disposal must be in accordance with local requirements. Pregnant healthcare personnel should not handle and/or administer Metoject PEN.
Methotrexate should not come into contact with the skin or mucosa. In the event of contamination, the affected area must be rinsed immediately with ample amount of water.
For single use only.
Any unused medicinal product or waste should be disposed of in accordance with local requirements.
The most appropriate zones for the injection are:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.